Technology Prognosis

tracking technologies before you have to make a decision

Prognosis is a horizon scanning service that monitors emerging health technologies as they go through clinical trial development and the regulatory approval process.

View a sampling of our Prognosis reports.

Viaskin Epicutaneous Immunotherapy (EPIT) for Peanut Allergy

March 21, 2019 Technology Prognosis

Viaskin Peanut is an epicutaneously delivered immunotherapy in development for the treatment of peanut allergy. The Viaskin patch contains antigen in dry form, which adheres to a central backing surrounded by an adhesive crown that secures the patch to the skin, creating an occlusive chamber. The patch is applied once daily. The Viaskin patch works by gradually exposing the patient to an allergen. After the patch is applied, the allergen is concentrated in the superficial layers of the skin, where it activates the immune system.

Zulresso (Brexanolone) for Postpartum Depression

March 20, 2019 Technology Prognosis

Brexanolone is a sterile solution of allopregnanolone for intravenous infusion in development for the treatment of postpartum depression (PPD). Allopregnanolone is a positive allosteric modulator of the neurotransmitter gamma-aminobutyric acid (GABAA) receptors. Plasma allopregnanolone concentrations rise in concert with progesterone throughout pregnancy, reaching the highest physiological concentrations in the third trimester. After childbirth, these concentrations decrease abruptly. Failure of GABAA receptors to adapt to these changes may have a role in triggering PPD. Although the cause of PPD is not entirely understood, it is proposed that treatment of women with PPD with doses of allopregnanolone that result in serum concentrations...

Celiprolol (Proposed Name: Edsivo) for Vascular Ehlers-Danlos Syndrome

March 19, 2019 Technology Prognosis

Celiprolol is an oral beta-1 adrenoceptor antagonist with partial beta-2 agonist activity proposed for the prevention of complications of vascular Ehlers-Danlos syndrome (EDS). Celiprolol has antihypertensive and antianginal properties, in addition to influencing vascular tone and smooth muscle. Celiprolol is believed to provide clinical benefit for people with vascular EDS by promoting normal collagen synthesis in the blood vessels, and by shifting the pressure load away from the vessels most prone to dissection and rupture.

Early Bird Bleed Monitoring System

March 13, 2019 Technology Prognosis

The Early Bird Bleed Monitor System (EBBMS) is comprised of a standard vascular access sheath with embedded sensors that measure the electrical resistance across the blood vessel. By sensing a change in the vessel’s electrical resistance, the EBBMS is designed to detect and monitor bleeding from a blood vessel accidentally injured during endovascular procedures. When there is a vessel injury at the femoral access site, blood begins to accumulate outside the vessel, causing a change in impedance; a user interface display alerts the user to the change in impedance and a potential bleeding complication. The EBBMS is sensitive enough to...

Andexxa (Coagulation Factor Xa [recombinant], inactivated-zhzo)

March 12, 2019 Technology Prognosis

Andexxa is an inactive modified recombinant factor Xa molecule that competes with circulating levels of factor Xa to bind directly with factor Xa inhibitors. It is administered intravenously. The FDA approved Andexxa in May 2018 for use in patients being treated with Xarelto and Eliquis, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. The FDA granted Andexxa an accelerated approval for this indication, based on the change from baseline in anti-factor Xa activity in healthy volunteers. Continued approval may be contingent upon the results of FDA mandated postmarket studies to demonstrate an improvement in hemostasis in...